2-[(2-fluoro-5-nitrobenzyl)amino]ethanol | 216008-35-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(2-fluoro-5-nitrobenzyl)amino]ethanol
• 英文别名: 2-(2-fluoro-5-nitro-benzylamino)-ethanol；2-[(2-fluoro-5-nitrophenyl)methylamino]ethanol
• CAS: 216008-35-4
• 化学式: C₉H₁₁FN₂O₃
• 分子量: 214.196
• InChiKey: INAQXHNJZACERP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(2-fluoro-5-nitrobenzyl)amino]ethanol 在 sodium chlorite 、 sodium dihydrogenphosphate 、 草酰氯 、 二甲基亚砜 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 环己烯 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 二甲基亚砜 、 乙腈 、 叔丁醇 为溶剂， 反应 75.83h， 生成 1-(tert-butoxycarbonyl)-5-((2S)-4-carboxymethyl-7-nitro-3-oxo-2,3,4,5-tetrahydro-1H-benzo[1,4]diazepin-2-ylmethyl)imidazole
  参考文献：
  名称：

  A Selective AT₂ Receptor Ligand with a γ-Turn-Like Mimetic Replacing the Amino Acid Residues 4−5 of Angiotensin II

  摘要：

  Three angiotensin II (Ang II) analogues encompassing a benzodiazepine-based gamma-turn-like scaffold have been synthesized. Evaluation of the compounds in a radioligand binding assay showed that they had no affinity to the rat liver AT(1) receptor. However, one of the compounds displayed considerable affinity to the pig uterus AT(2) receptor (K-i = 3.0 nM) while the other two lacked affinity to this receptor. It was hypothesized that the reason for the inactivity of one of these analogues to the AT(2) receptor was that the guanidino group of the Arg(2) residue and/or the N-terminal end of the pseudopeptide could not interact optimally with the receptor. To investigate this hypothesis, a conformational analysis was performed and a comparison was carried out with the monocyclic methylenedithioether analogue cyclo(S-CH2-S) [CyS3,5]-Ang II which is known to bind with high affinity to the AT(2) receptor (K-i = 0.62 nM). This comparison showed that, in the compounds with high AT(2) receptor affinity, the guanidino group of the Arg(2) residue and the N-terminal end could access common regions of space that were not accessible to the inactive compound. To examine the importance of the guanidino group for binding, the Arg side chain was removed by substituting Arg(2) for Ala(2) in the analogue having the high affinity. This analogue lacked affinity to AT(2) receptors, which supports the role of the guanidino group in receptor binding.

  DOI：

  10.1021/jm030921v
• 作为产物：
  描述：

  苯甲醛 、 C.I.酸性橙108 在 溶剂黄146 、 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 22.5h， 以83%的产率得到2-[(2-fluoro-5-nitrobenzyl)amino]ethanol
  参考文献：
  名称：

  WO2008/51547

  摘要：

  公开号：

文献信息

• Amidine derivatives as inhibitors of nitric oxide synthase
  申请人：AstraZeneca AB

  公开号：US06489322B1

  公开（公告）日：2002-12-03

  There are provided novel compounds of formula (I) wherein R1 represents a 2-thienyl or 3-thienyl ring and R2 represents hydrogen or C 1 to 4 alkyl and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are selective inhibitors of the neuronal isoform of nitric oxide synthase.

  提供了以下化合物的新颖化合物（I）的公式，其中R1代表2-噻吩基或3-噻吩基，R2代表氢或C1至C4烷基及其光学异构体和消旋体以及药学上可接受的盐；以及它们的制备过程，含有它们的组合物以及它们在治疗中的用途。这些化合物是神经型一氧化氮合酶的选择性抑制剂。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。
• AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE
  申请人：Astra Aktiebolag

  公开号：EP0983268A1

  公开（公告）日：2000-03-08
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS
  申请人：Cephalon, Inc.

  公开号：EP2222647A1

  公开（公告）日：2010-09-01